Team

Mark R. Saunders
President
mark.saunders@achelous.com

As President of Achelous Partners, Mark is a leading investment banker to international public and private life science companies. He has a successful history of cross border mergers and acquisitions and cross border joint ventures.

Mark has significant expertise in the US listing process and in all forms of financing available to domestic and international companies. He leverages his extensive contacts both on Wall Street and in the international financial markets to maximize financial opportunities for our clients with market makers, international traders, institutional public and private funds and high net worth investors.

Mark was general outside legal counsel to Citibank's ADR Division, undertaking over 300 transactions involving non-US companies listing on NASDAQ and the New York Stock Exchange. He was head of Greenberg Traurig's International Corporate Finance Group, where he advised and assisted non-US companies to issue securities in the US capital markets, representing companies from Australia, the United States, Latin America, Europe and Asia. Mark was also a Partner with the US law firms of Brown & Wood and Parker Chapin, specializing in securities and corporate finance. Mark holds a Juris Doctor from New York Law School and is a member of the New York Bar Association.

Dr. Jan Boesen
European Representative
jan.boesen@achelous.com

Jan Boesen focuses on deal origination and developing various corporate strategies for the European market. Using his long-term management experience in the biotech and diagnostic industry, he advises on and supports international mergers and acquisitions.

Jan Boesen has over 20 years "hands on" experience in the Life Sciences industry of which 16 years were in executive positions. He obtained his Ph.D. degree at Leiden University in 1992. He held various management positions in clinical development, operations and business development at Introgene (now Crucell-J&J). From 1999-2005, Jan Boesen was CEO of Amsterdam Molecular Therapeutics (AMT) B.V. (now UniQure, a publicly trading company). During this period, AMT brought a gene therapy for lipoprotein lipase (LPL) deficiency (Glybera) to the clinic. In 2012, Glybera became the first gene therapy approved by the European Commission. Furthermore, he was General Manager of BioConnection (spin-off from Organon-MSD) and COO of ISA Pharmaceuticals, a company developing therapeutic vaccines. From 2008-2015 he was CEO of IBL International, which develops, produces and sells immunodiagnostics products. During this period, IBL was transformed into a niche player with 50% increased turnover and 86 employees. In July 2014, IBL International was sold to the Tecan Group (Switzerland) for €29 million by Achelous Partners.

Eric L. Zitter
Director, New York
eric.zitter@achelous.com

Eric Zitter focuses on deal origination with a focus on domestic and cross-border mergers and acquisitions. Eric has researched and traveled globally searching for M&A opportunities for Achelous Partners’ international client base.

Previously, Eric was a Business Development Analyst at Quintiles Transnational, where he conducted research on potential blockbuster late Phase III/registered drugs as targets for new business opportunities, analyzed competitor companies as targets for possible acquisitions, and launched the company’s first weekly internal newsletter consisting of latest drug news, new drug approvals, and pipeline information. Eric holds a joint Bachelor of Science and Engineering in Bioengineering with a minor in Applied Economics from Cornell University.

Akshay Nadkarni
Director, New York
akshay.nadkarni@achelous.com

Akshay Nadkarni is involved in multiple activities across the firm ranging from leading full sell-side and buy-side M&A transactions to in-depth technology and corporate valuation analysis.

Akshay has managed over 25 M&A transactions with a combined transaction value of over $1.2 billion over the past ten years. He is focused on grasping the key value drivers of international life science clients in order to identify creative strategic M&A opportunities. As part of the M&A team, Akshay has managed cross-border transactions involving companies in several healthcare and life science fields, including life science technologies/tools/reagents, in vitro diagnostics, molecular diagnostics, CRO and other outsourced life science services, biopharmaceuticals, specialty pharmaceuticals, generics and healthcare IT. In addition, he has undertaken research involving emerging companies in various healthcare and biotechnology sectors. Akshay holds a Bachelor of Arts in Biology and Finance from New York University.

Overview
New York-based investment bank focused on Mergers and Acquisitions in the global life science and healthcare sectors.

Global Presence
Building management relationships throughout the US, Europe, Australia, Asia and Latin America.

Approach
Cultivating long-term relationships through senior-level attention and exerptise, objective advice and successful deal execution.

Recent News

June 2, 2017
Achelous Partners Advises Coté Orphan, LLC on its sale to QuintilesIMS

May 3, 2017
Achelous Partners Advises PharmaCell B.V. on its sale to Lonza Group Ltd.

April 25, 2017
Achelous Partners Advises Emergo Group, Inc. on its sale to UL LLC

  • June 2017
    has been acquired by
    The undersigned acted as financial advisor to Coté Orphan, LLC
  • May 2017
    has been acquired by
    The undersigned acted as financial advisor to PharmaCell B.V.
  • April 2017
    has been acquired by
    The undersigned acted as financial advisor to Emergo Group, Inc.
  • April 2017
    has been acquired by
    The undersigned acted as financial advisor to Calbiotech, Inc.
  • January 2017
    has been acquired by
    The undersigned acted as financial advisor to BioControl Systems, Inc.
  • August 2016
    has been acquired by
    The undersigned acted as financial advisor to SPEware Corporation
  • July 2016
    has acquired
    The undersigned acted as financial advisor to Sharps Compliance Corp.
  • June 2016
    has been acquired by
    The undersigned acted as financial advisor to Cisbio Bioassays
  • December 2015
    has acquired
    The undersigned acted as financial advisor to Abzena plc
  • December 2015
    has acquired
    The undersigned acted as financial adviser to Sharps Compliance Corp.
  • October 2015
    has been acquired by
    The undersigned acted as financial advisor to Kinesis Pharma BV
  • August 2015
    has been acquired by
    The undersigned acted as financial advisor to DIAsource ImmunoAssays SA
  • July 2015
    has acquired
    The undersigned acted as financial advisor to Sharps Compliance Corp.
  • March 2015
    has acquired
    The undersigned acted as financial advisor to Ansell Limited
  • July 2014
    has been acquired by
    The undersigned acted as financial advisor to IBL International Holding BV
  • July 2014
    has been acquired by
    The undersigned served as financial advisor to Phlexglobal Limited
  • June 2014
    has been acquired by
    The undersigned served as financial advisors to Pharmalink Consulting
  • December 2013
    has acquired assets from
    The undersigned acted as advisor to Valeant Pharmaceuticals International
  • August 2013
    has been acquired by
    The undersigned acted as financial advisor to Kirkegaard & Perry Laboratories Inc
  • July 2013
    has been acquired by
    The undersigned acted as financial advisor to The Anson Group LLC
  • July 2013
    has signed a definitive agreement to sell its orthopedic implant assets and business to
    an Apax Partners company The undersigned acted as financial advisor to Austofix Group Limited
  • July 2013
    has been acquired by
    The undersigned acted as financial advisor to Kreatech Holding B.V.
  • July 2013
    has been acquired by
    USD$10,000,000
    The undersigned acted as financial advisor to Matrical Bioscience Inc
  • May 2013
    has been acquired by
    The undersigned acted as advisor to Triangle Biomedical Sciences Inc.
  • August 2012
    has been acquired by
    The undersigned acted as advisor to JSW Life Sciences GmbH
  • March 2012
    has acquired assets from
    US$164M plus up to US$20M in milestones
    The undersigned acted as advisor to Valeant Pharmaceuticals International
  • December 2011
    invests in
    The undersigned acted as advisor to Ansell Limited for the investment
  • August 2010
    has been acquired by
    The undersigned acted as financial advisor to EnviroLogix, Inc.
  • March 2010
    has been acquired by
    USD$59,000,000
    The undersigned acted as financial advisor to Finnzymes Oy
  • December 2009
    has licensed its ReGet® drug delivery system for ophthalmic indications to
    The undersigned acted as financial advisor to BTG olc
  • October 2009
    has been acquired by
    The undersigned acted as financial advisor to Anaspec Inc.
  • August 2009
    has sold its HySolv™ drug delivery technology to
    The undersigned acted as financial advisor to BTG plc
  • January 2009
    has been acquired by
    The undersigned acted as financial advisor to the shareholders of Labcoat Limited
  • December 2008
    has acquired
    The undersigned is acting as financial advisor to Biocompatibles International
  • December 2008
    has acquired
    The undersigned rendered a Fairness Opinion to Affymetrix, Inc.
  • February 2008
    has been acquired by
    The undersigned is acting as financial advisor to Sigma Pharmaceuticals
  • January 2008
    has been acquired by
    The undersigned is acting as financial advisor to Panbio Limited
  • May 2007
    has acquired
    The undersigned acted as financial advisor to Ansell Limited
  • March 2007
    has sold its Human Health point-of-care diagnostic products business to
    The undersigned acted as financial advisor to Agenix Limited
  • February 2007
    Strategic alliance and investment of up to £32,100,000 in
    The undersigned acted as financial advisor to GeneMedix, PLC
  • December 2006
    Announced M&A advisory and restructuring
    The undersigned acted as financial advisor to Panbio Limited
  • December 2006
    has acquired
    The undersigned acted financial advisor to Novozymes A/S
  • August 2006
    has acquired
    The undersigned acted as financial advisor to Meditech Research Limited
  • July 2006
    has acquired Delta Biotechnology Ltd from
    The undersigned acted as financial advisor to Novozymes A/S
  • April 2006
    has assigned IP and granted distribution rights for its Animal Health business to
    The undersigned acted as financial advisor to Agenix Limited
  • October 2005
    M&A advisory and valuation analysis
    The undersigned acted as financial advisor to CogState Limited
  • September 2005
    NASDAQ listing of ADRs (American Depositary Receipts)
    The undersigned acted as advisor to Genetic Technologies Limited
  • June 2005
    NASDAQ listing of ADRs (American Depositary Receipts)
    The undersigned acted as advisor to ChemGenex Pharmarceuticals Limited
  • January 2005
    awarded to
    for its investment banking role in the creation of
  • December 2004
    has been acquired by
    The undersigned acted as financial advisor to AGT Biosciences Ltd.
Top